ImStem Biotechnology to present at 2022 Cell & Gene Meeting On the MESA

Rami Levin, Chief Executive Officer, and Xiaofang Wang, Chief Technology Officer, will give an update on the company’s latest advances in its first-in-class T-MSC （IMS001）cell therapy product development and clinical trial on multiple sclerosis.

Organized by the Alliance for Regenerative Medicine, the annual Cell & Gene Meeting on the Mesa is the sector’s foremost conference, bringing together senior executives and top decision-makers in the industry to advance cutting-edge research in this field. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, more than 1,700 attendees, and over 100 dedicated presentations by the leading publicly traded and privately held companies.

“It is our great honor to be invited to present at such a high-profile conference, the first one following the Covid-19 Pandemic,” said Rami Levin, CEO of ImStem. “It is truly an encouraging recognition for ImStem’s work and ongoing pursuit of cutting-edge stem cell therapies”.

Video of the corporate presentation will be posted on www.imstem.com when it becomes available.